Core Insights - The biomanufacturing industry in China has experienced significant growth during the "14th Five-Year Plan" period, becoming a crucial force for optimizing and upgrading the economic structure [1] Group 1: Industry Scale and Growth - The total scale of China's biomanufacturing industry has steadily expanded, reaching 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [1] - The annual output value of sub-sectors such as food additives and biopharmaceuticals exceeds 400 billion yuan, establishing biomanufacturing as a new economic growth point [1] Group 2: Technological Innovation - China's biomanufacturing sector has shown remarkable innovation, with over 20% of global patent applications originating from this field [2] - A number of national key laboratories and industrial innovation platforms have been established, leading to the industrial application of new instruments such as domestic high-throughput gene sequencers and large-scale fermentation tanks [2] Group 3: Industrial Cluster Development - Major cities like Beijing and Tianjin have emerged as innovation hubs for biomanufacturing, while provinces such as Shandong, Heilongjiang, and Henan have developed into manufacturing bases for bulk bioproducts [3] - The biomanufacturing sector has cultivated several backbone enterprises with annual revenues exceeding 10 billion yuan, along with dozens of national-level manufacturing champions and specialized "little giant" enterprises [3] - More than 40 pilot capacity-building platforms and high-quality incubators have been established to support the industry [3]

Group 1 - The State-owned Assets Supervision and Administration Commission (SASAC) plans to guide central enterprises in deepening and expanding AI initiatives during the 14th Five-Year Plan, focusing on key areas such as new energy, new energy vehicles, new materials, aerospace, and low-altitude economy, while also planning for advanced fields like quantum technology, embodied intelligence, biomanufacturing, and 6G [1] - The Central Economic Work Conference highlighted that integrating technological innovation with industrial innovation is a key focus for economic work in the coming year, with an emphasis on innovation-driven growth and nurturing new economic drivers as a priority task following domestic demand expansion [1][3] Group 2 - Wanhe Securities noted an increasing urgency in cultivating new economic drivers, as the emphasis has shifted from merely proposing the development of new drivers to a more structured approach that balances the cultivation of new and the updating of old drivers, driven by external pressures and internal challenges [3] - The report anticipates that as the AI+ initiative progresses, AI is expected to accelerate its transformation into productivity across various sectors including industry, agriculture, and services, with a significant impact on total factor productivity by 2026, driven by both funding and policy support [3]

（原标题：南财早新闻｜网信办、证监会出手！严打资本市场谣言） 3、商务部公布数据显示，1-11月，全国实际使用外资金额6931.8亿元人民币，同比下降7.5%。11月当 月实际使用外资同比增长26.1%。 4、国务院国资委主任张玉卓表示，"十五五"时期，将指导推动央企深化拓展"AI "专项行动，接续发力 新能源、新能源汽车、新材料、航空航天、低空经济等重点领域，超前谋划量子科技、具身智能、生物 制造、6G等前沿赛道。 5、据财政部消息，山西省、青海省自2026年1月1日起，按照有关规定实施境外旅客购物离境退税政 策。 6、商务部19日发布公告，对原产于美国、韩国和欧盟的进口三元乙丙橡胶继续征收反倾销税。 7、19日，中国人民银行等三部门对外发布《人民币现金收付及服务规定》，其中提到，除因履行法 律、法规、规章规定的义务或法定职责而应使用非现金支付工具情形外，不得拒收现金。规定将自2026 年2月1日起施行。 8、19日，四川攀枝花金沙江银江水电站最后一台机组顺利并网。至此，四川水电装机容量突破1亿千 瓦，约占全国水电装机总量的四分之一。 1、贵州证监局依法严肃查处贵州百灵财务造假案，拟对贵州百灵处以1000万 ...

每经记者｜杨欢 每经编辑｜刘艳美 据工业和信息化部官网消息，根据《关于开展生物制造中试能力建设平台培育工作的通知》(工信厅联消费函〔2025〕234号)，经省级主管部 门推荐、专家评价、面向社会公示等程序，工业和信息化部办公厅近日印发《生物制造中试能力建设平台名单(第一批)》。共有43个平台入 选。 工业和信息化部将按年度组织专家对列入名单的平台软硬件水平、对外开展中试服务的数量及质效等方面进行评估，动态调整平台服务能力星 级，对服务能力、服务效果达不到要求以及知识产权、安全生产、环境保护、质量安全等方面出现严重违法违规情况的平台予以除名。 解读：所谓"生物制造"是一种新兴的生产技术，通过生物过程来合成或加工产品，与传统的化学或物理制造方法相比，具有绿色、高效、可再 生等特点，在医药、食品、化工等领域应用前景广阔。 继2025年政府工作报告首次将生物制造作为未来产业提出后，国家"十五五"规划建议也将生物制造列为应前瞻布局的新增长点。地方早已开始 行动，过去五年，包括上海、北京、江苏、广东等20余个省份出台了生物制造产业提振政策，多个相关专项基金陆续建立。 目前，全国生物制造产业总规模达到1.1万亿元，生物发酵 ...

据工业和信息化部官网消息，根据《关于开展生物制造中试能力建设平台培育工作的通知》(工信厅联消费函〔2025〕234号)，经省级主管部 门推荐、专家评价、面向社会公示等程序，工业和信息化部办公厅近日印发《生物制造中试能力建设平台名单(第一批)》。共有43个平台入 选。 中试是生物科技创新成果向工业生产转化的关键环节。研究表明，生物制造创新成果经过中试产业化成功率可达80%；而未经过中试的，产业 化成功率只有30%。随着我国生物制造产业发展，一大批生物制造初创企业涌现。面对爆发式的中试验证需求，需要更多的中试平台和基地， 帮助企业跨越"创新"与"产业"之间的"死亡谷"。 今年6月，工业和信息化部、国家发展改革委联合发布《关于开展生物制造中试能力建设平台培育工作的通知》，提出到2027年，力争培育生 物制造中试能力建设平台20个以上，服务企业数量超过200家，孵化产品400个以上。 中试平台数量一定程度上反映了各地的产业转化能力。从此次公布的名单来看，34个平台分布在全国25个省份中。从入选数量来看，江苏、湖 北各有4个平台入选，排名第一，位列其后的天津、上海、浙江、山东，各有3个平台入选。 工业和信息化部将按年度 ...

Core Insights - The biomanufacturing industry in China has reached a total scale of 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [1] - Biomanufacturing is recognized as a strategic emerging industry that can drive new economic growth and foster innovation across pharmaceuticals, chemicals, and fuels [1] Industry Development - Biomanufacturing utilizes industrial biotechnology, including genetic engineering and synthetic biology, to process and convert materials through microorganisms, enzymes, or cells, with applications in pharmaceuticals, new materials, renewable energy, ecological protection, and modern agriculture [2] - The Chinese government has implemented multiple policies to support the development of the biomanufacturing industry, aiming to cultivate over 20 pilot platforms by 2027, serving more than 200 enterprises and incubating over 400 products [2] - Local governments are actively creating high-end biomanufacturing clusters, with regions like Beijing, Shanghai, Guangdong, and Zhejiang introducing supportive policies and establishing specialized funds for industry development [2] Innovation and Collaboration - The synergy of policy, capital, and technological innovation is providing strong support for the industrialization of biomanufacturing, creating a resilient and dynamic industry ecosystem [3] - Numerous listed companies are entering the biomanufacturing sector to capitalize on market opportunities, with strategic collaborations being formed, such as the partnership between Lude Biological Environmental Technology Co., Ltd. and Zhejiang Hanghua New Materials Technology Co., Ltd. [3][4] Market Applications - In the field of medical health, Wuhan Heyuan Biotechnology Co., Ltd. has developed several pharmaceutical products using rice endosperm cell bioreactors, with one of its innovative drugs being recognized as a landmark biomanufacturing product for 2024 [4] - Shanghai Kaysai Biotechnology Co., Ltd. is focusing on new bio-based materials, developing bio-based polyamide composite materials that are competitive with metals in strength while significantly reducing carbon emissions compared to traditional petroleum-based products [4] - The biomanufacturing industry is expected to see significant breakthroughs in replacing fossil raw materials in various sectors, including chemical materials, aviation fuels, and textile fibers, driven by increasing environmental awareness and technological advancements [4][5]

Core Insights - The article highlights the transformation of Jia Bi You Biotechnology (Wuhan) Co., Ltd. from a single nutrient supplier to a synthetic biology platform enterprise over six years since its listing on the Sci-Tech Innovation Board, marking a significant milestone in China's food biotechnology sector [1] Financial Performance - Jia Bi You's revenue has grown from 312 million yuan in 2019 to 555 million yuan in 2024, achieving a compound annual growth rate (CAGR) of 12.2% [2] - In 2025, the company reported a revenue of 428 million yuan and a net profit of 129 million yuan in the first three quarters, reflecting a year-on-year increase of 54.18%, surpassing the total net profit for 2024 [2] - As of December 19, 2025, the company's market capitalization exceeded 3.9 billion yuan, demonstrating significant growth since its initial public offering [2] Product Development and Market Position - The company has expanded its product matrix, achieving over 40% global market share in ARA (Arachidonic Acid) and surpassing 100 million yuan in annual sales for DHA (Docosahexaenoic Acid) [2] - Jia Bi You has developed a diverse product system covering human nutrition, animal nutrition, and personal care, with 114 authorized products for SA (Sialic Acid) [2] - The successful mass production of 2'-fucosyllactose (2'-FL) in 2025 fills a significant gap in China's HMO (Human Milk Oligosaccharides) market [2] Supply Chain and Risk Management - The company has established a fully controllable supply chain, achieving domestic substitution across the entire production process from strain cultivation to fermentation and product application [3] - The second phase of the Wuhan production base has positioned the company among the global leaders in ARA and DHA production capacity [3] - Jia Bi You's products have received international certifications and are exported to over 30 countries, establishing stable partnerships with global giants like Nestlé [3] Research and Development - Jia Bi You maintains a research and development investment of over 8%, with 2024 R&D expenditure reaching 47.9 million yuan, a 24.12% increase year-on-year [4] - The company has developed a full-stack technology loop integrating AI and synthetic biology, breaking foreign monopolies in industrial strains [4] - The establishment of a national pilot platform for microbial fermentation supports the transition from laboratory to production line [4] Industry Standards and Future Strategy - Jia Bi You has actively participated in the formulation of national food safety standards and was selected for the national synthetic biology standardization project research group in 2025 [5] - The company aims to focus on high-end equipment development and advanced molecular layout, targeting the trillion-yuan market outlined in the 14th Five-Year Plan [5] - Future plans include upgrading the pilot platform to a public service hub for bio-manufacturing and deepening global cooperation to expand into European, American, and Southeast Asian markets [5]

Core Insights - 36Kr, as China's largest new economy media platform, has significantly enhanced financing opportunities for enterprises through deep collaboration with investment institutions and fund partners, accumulating a wealth of primary market investor resources over the past decade [1] - The "Daily Roadshow" provides a new type of online closed-door roadshow for high-quality entrepreneurial projects, facilitating deep operational services for both entrepreneurs and investors [1] Project Summaries - **Yuyou Technology**: Focuses on AI-driven new material prediction models, aiming to redefine material R&D paradigms. The project seeks A-round financing of 25-70 million RMB, highlighting a paradigm-level technological breakthrough that reduces R&D cycles by 80% and costs by 70% [3][4] - **Blue Vector**: Develops eVTOL aircraft and aviation software, seeking Pre-A round financing of 100 million RMB. The V30 model meets high safety standards and is designed with a software-defined aircraft concept [6] - **Millis Control**: A leading company in line-controlled steering systems, seeking Pre-A round financing of 50 million RMB. The founding team has experience in developing national standards and has a strong technical background [8][9] - **Bai Shi Electronics**: Specializes in third-generation semiconductor materials, seeking B+ round financing of 100 million RMB. The company has a high yield rate for its silicon carbide products and has established a complete R&D and production center [10] - **Zhongke Guosheng**: A pioneer in bio-based materials, focusing on the innovation and industrialization of furan-based chemicals. The project seeks B round financing of 100-150 million RMB, boasting a unique continuous process that significantly reduces production costs [12][13] - **Hanhai Juneng**: The first commercial company in China focusing on controllable nuclear fusion technology, seeking Pre-A round financing of 200 million RMB. The project has achieved significant milestones in developing a linear field-reversed configuration fusion device [15][16]

德勤中国资本市场服务部上市业务华北及华西区主管合伙人任绍文认为，港股市场的表现得益于港交所 和香港证监会推行多项改革措施，例如简化上市审批程序、缩短新股结算周期，以及首次公开招股市场 定价机制等。 另据报告预计，截至今年12月31日，中国内地A股市场共有114只新股上市，数量同比增加14%，融资 总额为1296亿元人民币，同比增长94%。 "预计2026年A股表现将比今年更出色。"德勤中国资本市场服务部华北区上市业务合伙人陈文龙说，来 自人工智能、新能源、高端制造、商业航天、量子技术和生物制造等领域的企业，在A股市场上市和融 资时料将获得更大优势。(完) 来源：中国新闻网 德勤预计明年香港新股市场融资额突破3000亿港元 中新社北京12月18日电 (陶思阅)德勤中国资本市场服务部18日在北京发布《中国内地及香港IPO市场 2025年回顾与2026年前景展望》报告，预计明年香港新股市场有望再创融资额纪录，至少达到3000亿港 元。 报告预计，今年全年将有114只新股在香港上市，数量较去年上涨63%，融资总额为2863亿港元，同比 增长227%。 在目前超过300宗上市申请个案的名单支持下，2026年全年，香港新 ...

今日关注 新股申购：双欣环保（深）、誉帆科技（深）、强一股份（科）。新股上市：优迅股份。 山东举行介绍省属国资国企深化改革推动高质量发展情况的发布会 周大福天猫官方旗舰店：受市场因素影响，部分商品即将提价，调价窗口为12月19日 今日有1205亿元7天期逆回购到期 2025进博优品交易会将于12月19日至21日在上海举办 摩尔线程MUSA开发者大会定档12月19日，将发布全新产品和架构 第五届碳中和博鳌大会将于12月19日至20日举办 电影《阿凡达3》将于12月19日正式上映 美团无人机低空航网发布会将于12月19日举办 日本央行公布利率决议 美国司法部发布杰弗里·爱泼斯坦相关文件的截止日期 俄罗斯总统普京举行年度记者会 拟公布经济数据：日本11月CPI、德国11月PPI、英国零售销售、美国12月密歇根大学消费者信心指数、 中国11月全社会用电量。 隔夜市场 美股三大指数集体收涨，道指涨0.14%，纳指涨1.38%，标普500指数涨0.79%，热门科技股普涨，美光 科技涨超10%，特斯拉涨超3%。纳斯达克中国金龙指数收涨0.97%，热门中概股多数上涨。 COMEX黄金期货收跌0.23%，报4363.9美元/盎 ...